Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Verastem, Inc.
  6. News
  7. Summary
    VSTM   US92337C1045

VERASTEM, INC.

(VSTM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Verastem : Oncology Names Louis Denis Chief Medical Officer

09/22/2021 | 08:03am EDT


© MT Newswires 2021
All news about VERASTEM, INC.
09/30Verastem Oncology Reports the Appointment of Louis J. Denis as Chief Medical Officer
CI
09/24VERASTEM ONCOLOGY : Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
09/22VERASTEM : Oncology Names Louis Denis Chief Medical Officer
MT
09/22VERASTEM ONCOLOGY : Appoints Louis J. Denis, M.D., as Chief Medical Officer
BU
09/22Verastem Oncology Appoints Louis J. Denis, M.D., as Chief Medical Officer
CI
09/20Health Care Stocks Sink with Broader Markets
MT
09/20VERASTEM : Amgen to Evaluate VS-6766, Sotorasib Combo Therapy in Non-Small Cell Lung Cance..
MT
09/20Wall Street Futures Tumble as China's Evergrande Default Risk Weighs on Sentiment
MT
09/20Health Care Stocks Trade Lower Pre-Bell Monday
MT
09/20VERASTEM : Health Care
MT
More news
Analyst Recommendations on VERASTEM, INC.
More recommendations
Financials (USD)
Sales 2021 1,43 M - -
Net income 2021 -63,5 M - -
Net Debt 2021 - - -
P/E ratio 2021 -7,69x
Yield 2021 -
Capitalization 486 M 486 M -
Capi. / Sales 2021 340x
Capi. / Sales 2022 38,9x
Nbr of Employees 49
Free-Float 99,3%
Chart VERASTEM, INC.
Duration : Period :
Verastem, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VERASTEM, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 2,69 $
Average target price 6,25 $
Spread / Average Target 132%
EPS Revisions
Managers and Directors
Brian M. Stuglik Chief Executive Officer & Director
Daniel W. Paterson President & Chief Operating Officer
Robert E. Gagnon Chief Financial & Business Officer
Jonathan Pachter Chief Scientific Officer
Louis J. Denis Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
VERASTEM, INC.26.29%486
GILEAD SCIENCES, INC.14.83%83 880
WUXI APPTEC CO., LTD.29.16%66 875
BIONTECH SE222.44%63 484
REGENERON PHARMACEUTICALS14.28%57 402
VERTEX PHARMACEUTICALS-21.55%48 101